Message #87 From:
NewsBot Date: November 26, 2007 02:24:54 PM
MIV Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
MIV Therapeutics, Inc. (OTCBB: MIVT)
(FRANKFURT: MIV), a leading developer of next-generation coatings and
advanced drug delivery systems for cardiovascular stents and other
implantable medical devices, today announced that Dr. Mark Landy, president
of MIV Therapeutics, will present a company overview at the BMO Capital
Markets Focus On Healthcare Conference on December 4, 2007 at 2:30 p.m.
Eastern Time. The conference will be held at Millennium Broadway Hotel in
New York City on December 4th and 5th.
The presentation will be available live via webcast on December 4, 2007 and
for 90 days thereafter. The webcast can be accessed by visiting the
investor relations section of the company's website at
www.mivtherapeutics.com.
About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced
biocompatible coatings for passive and drug-eluting applications on
cardiovascular stents, as well as for a broad range of other implantable
medical devices. The Company's ultra-thin coating formulation is designed
to protect surrounding tissue from potentially harmful interactions with
bare metallic stents. This coating platform is derived from hydroxyapatite
(HAp), an organic material that has demonstrated excellent in vivo safety
and biocompatibility. Hydroxyapatite is a porous material that makes up
the bone mineral and matrix of teeth, and is widely used today as a bone
substitute material and for coatings on implantable fixation devices in
orthopedic, dental and other applications. The Company's novel
polymer-free drug-eluting technologies based on HAp could also provide an
attractive alternative to current polymer-based drug-eluting coatings on
the stent market, which have been associated with undesirable effects. The
Company's drug-eluting coatings are additionally designed to suit a broad
range of implantable medical devices that could benefit from highly
customizable drug release profiles. MIV Therapeutics has a Collaborative
Research Agreement with the University of British Columbia and has received
a government grant for its research program on the "Development of Novel
Drug Eluting Composite Coatings for Cardiovascular Stents," under the
National Research Council-Industrial Research Assistance Program. Under
this sponsorship, the Company is expected to complete its drug-eluting
research and development program and to reach product commercialization.
MIV's intellectual property portfolio includes patents held by the
University of British Columbia and exclusively licensed to MIV. Key patent
applications filed simultaneously in various countries around the world
further protect the commercial exclusivity of MIV's inventions in the
global marketplace. For more information, please visit
www.mivtherapeutics.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters
discussed in this press release are forward-looking statements. Such
statements are indicated by words or phrases such as "proposed,"
"expected," "believe," "will," "breakthrough," "significant," "indicated,"
"feel," "revolutionary," "should," "ideal," "extremely" and "excited."
These statements are made under "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are
subject to risks and uncertainties including, without limitation, the
closing of the Share Purchase Agreement, the ability of the Company to
raise sufficient funding and to continue to develop its various business
interests as presently contemplated. See the Company's filings with the
Securities and Exchange Commission including, without limitation, the
Company's recent Form 10-K and Form 10-Qs, which identify specific factors
that may cause actual results or events to differ materially from those
described in the forward-looking statements.
